Discussion
Aspen Neuroscience has completed dosing in the third and fourth groups of people with Parkinson’s disease receiving its new commercial-ready formulation of the cell therapy sasineprocel (ANPD001) in a small U.S. clinical trial. This brings the total number of adults with Parkinson’s who received sasineprocel in the…
